Autosomal recessive polycystic kidney disease: A hepatorenal fibrocystic disorder with pleiotropic effects

Pediatrics

Volumn 134, Issue 3, 2014, Pages e833-e845

  Hartung, Erum A ^a   Guay Woodford, Lisa M ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Congenital hepatic fibrosis; Dialysis; Genetic testing; Kidney transplantation; Liver transplantation; Polycystic kidney disease; Preimplantation genetic diagnosis

Indexed keywords

FIBROCYSTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ARTIFICIAL VENTILATION; CHROMOSOME 6P; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; END STAGE RENAL DISEASE; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GROWTH DISORDER; HEPATOBILIARY DISEASE; HEPATORENAL FIBROCYSTIC DISORDER; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG HYPOPLASIA; NEPHRECTOMY; NONHUMAN; PERINATAL MORTALITY; PERITONEAL DIALYSIS; PKHD1 GENE; PRENATAL DIAGNOSIS; PROGNOSIS; PSYCHOSOCIAL CARE; RADIODIAGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; URINARY TRACT INFECTION; ANIMAL; CONGENITAL LIVER FIBROSIS; DIALYSIS; GENETIC DISORDER; GENETICS; LIVER CIRRHOSIS; PLEIOTROPY; PREIMPLANTATION GENETIC DIAGNOSIS;

CONGENITAL HEPATIC FIBROSIS; DIALYSIS; GENETIC TESTING; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POLYCYSTIC KIDNEY DISEASE; PREIMPLANTATION GENETIC DIAGNOSIS;

ANIMALS; GENETIC DISEASES, INBORN; GENETIC PLEIOTROPY; HUMANS; LIVER CIRRHOSIS; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE;

EID: 84907205578     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3646     Document Type: Review

References (143)

1. Zerres K, Mücher G, Becker J, et al. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): molecular genetics, clinical experience, and fetal morphology. Am J Med Genet. 1998; 76(2):137-144
2. Roy S, Dillon MJ, Trompeter RS, Barratt TM. Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors. Pediatr Nephrol. 1997;11(3):302-306
3. Kaplan BS, Fay J, Shah V, Dillon MJ, Barratt TM. Autosomal recessive polycystic kidney disease. Pediatr Nephrol. 1989;3(1):43-49
4. Kääriäinen H, Jääskeläinen J, Kivisaari L, Koskimies O, Norio R. Dominant and recessive polycystic kidney disease in children: classification by intravenous pyelography, ultrasound, and computed tomography. Pediatr Radiol. 1988;18(1):45-50
5. Adeva M, El-Youssef M, Rossetti S, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore). 2006;85(1): 1-21 doi:10.1097/01.md.0000200165.90373.9a
6. Bergmann C, Senderek J, Windelen E, et al; APN (Arbeitsgemeinschaft für Pädiatrische Nephrologie). Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int. 2005; 67(3):829-848 doi:10.1111/j.1523-1755.2005. 00148.x
7. Zerres K, Rudnik-Schoneborn S, Deget F, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft fur Padiatrische, Nephrologie. Acta Paediatr. 1996;85(4):437-445
8. Capisonda R, Phan V, Traubuci J, Daneman A, Balfe JW, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: outcomes from a single-center experience. Pediatr Nephrol. 2003;18(2):119-126 doi: 10.1007/s00467-002-1021-0
9. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003;111(5 pt 1):1072-1080
10. Onuchic LF, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexintranscription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet. 2002; 70(5):1305-1317 doi:10.1086/340448
11. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002;30 (3):259-269 doi:10.1038/ng833
12. Bergmann C, Frank V, Küpper F, Schmidt C, Senderek J, Zerres K. Functional analysis of PKHD1 splicing in autosomal recessive polycystic kidney disease. J Hum Genet. 2006;51 (9):788-793 doi:10.1007/s10038-006-0022-4
13. Menezes LFC, Cai Y, Nagasawa Y, et al. Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int. 2004;66(4):1345-1355 doi:10.1111/j.1523-1755.2004.00844.x
14. Zhang MZ, Mai W, Li C, et al. PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci USA. 2004;101(8):2311-2316
15. Nagasawa Y, Matthiesen S, Onuchic LF, et al. Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene. J Am Soc Nephrol. 2002;13(9):2246-2258 doi:10.1097/01.ASN.0000030392.19694.9D
16. Ward CJ, Yuan D, Masyuk TV, et al. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet. 2003;12(20): 2703-2710 doi:10.1093/hmg/ddg274
17. Wang S, Luo Y, Wilson PD, Witman GB, Zhou J. The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. J Am Soc Nephrol. 2004;15(3):592-602 doi: 10.1097/01.ASN.0000113793.12558.1D
18. Bakeberg JL, Tammachote R, Woollard JR, et al. Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin. J Am Soc Nephrol. 2011;22(12):2266-2277 doi:10.1681/ASN.2010111173
19. Gallagher A-R, Esquivel EL, Briere TS, et al. Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1. Am J Pathol. 2008;172(2):417-429 doi:10.2353/ajpath.2008.070381
20. Zhang J, Wu M, Wang S, Shah JV, Wilson PD, Zhou J. Polycystic kidney disease protein fibrocystin localizes to the mitotic spindle and regulates spindle bipolarity. Hum Mol Genet. 2010;19(17):3306-3319 doi:10.1093/hmg/ddq233
21. Watnick T, Germino G. From cilia to cyst. Nat Genet. 2003;34(4):355-356 doi:10.1038/ng0803-355
22. Menezes LF, Germino GG. Polycystic kidney disease, cilia, and planar polarity. Methods Cell Biol. 2009;94(08):273-297 doi: 10.1016/S0091-679X(08)94014-0
23. Kotsis F, Boehlke C, Kuehn EW. The ciliary flow sensor and polycystic kidney disease. Nephrol Dial Transplant. 2013;28(3):518-526 doi:10.1093/ndt/gfs524
24. Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol. 2004;15(10):2528-2536 doi:10.1097/01.ASN.0000141055.57643.E0
25. Yoder BK. Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2007;18(5):1381-1388 doi:10.1681/ASN.2006111215
26. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011;364(16): 1533-1543 doi:10.1056/NEJMra1010172
27. Kim I, Li C, Liang D, et al. Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin. J Biol Chem. 2008;283(46): 31559-31566 doi:10.1074/jbc.M805452200
28. Kim I, Fu Y, Hui K, et al. Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol. 2008;19(3): 455-468 doi:10.1681/ASN.2007070770
29. Wang S, Zhang J, Nauli SM, et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol. 2007;27 (8):3241-3252 doi:10.1128/MCB.00072-07
30. Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet. 1997;16(2):179-183 doi: 10.1038/ng0697-179
31. Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA. 1997;94(13):6965-6970
32. Bertuccio CA, Caplan MJ. Polycystin-1C terminus cleavage and its relation with polycystin-2, two proteins involved in polycystic kidney disease. Medicina (B Aires). 2013;73(2):155-162
33. Autosomal Recessive Polycystic Kidney Disease (ARPKD/PKHD1) Mutation Database. Available at: http://www.humgen.rwth-aachen.de. Accessed August 14, 2013
34. Bergmann C, Küpper F, Dornia C, Schneider F, Senderek J, Zerres K. Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat. 2005;25(3):225-231 doi:10.1002/humu.20145
35. Bergmann C, Senderek J, Küpper F, et al. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat. 2004;23(5):453-463 doi:10.1002/humu.20029
36. Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol. 2007;18(5): 1374-1380 doi:10.1681/ASN.2007010125
37. Bergmann C, Senderek J, Sedlacek B, et al. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol. 2003;14(1):76-89 doi:10.1136/jmg.2005.032318
38. Furu L, Onuchic LF, Gharavi A, et al. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol. 2003;14(8):2004-2014
39. Sharp AM, Messiaen LM, Page G, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet. 2005;42(4):336-349 doi:10.1136/jmg.2004.024489
40. Bergmann C, Senderek J, Schneider F, et al. PKHD1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat. 2004;23(5):487-495 doi:10.1002/humu.20019
41. Denamur E, Delezoide AL, Alberti C, et al; Société Française de Foetopathologie. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int. 2010; 77(4):350-358 doi:10.1038/ki.2009.440
42. Losekoot M, Haarloo C, Ruivenkamp C, White SJ, Breuning MH, Peters DJM. Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD). Hum Genet. 2005;118(2):185-206 doi:10.1007/s00439-005-0027-7
43. Gunay-Aygun M, Tuchman M, Font-Montgomery E, et al. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Mol Genet Metab. 2010;99(2):160-173 doi:10.1016/j.ymgme.2009.10.010
44. Gunay-Aygun M, Font-Montgomery E, Lukose L, et al. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5(6): 972-984 doi:10.2215/CJN.07141009
45. Zerres K, Mücher G, Bachner L, et al. Mapping of the gene for autosomal recessive polycystic kidney disease (ARPKD) to chromosome 6p21-cen. Nat Genet. 1994; 7(3):429-432 doi:10.1038/ng0794-429
46. Mücher G, Wirth B, Zerres K. Refining the map and defining flanking markers of the gene for autosomal recessive polycystic kidney disease on chromosome 6p21.1-p12. Am J Hum Genet. 1994;55(6):1281-1284
47. Guay-Woodford LM, Muecher G, Hopkins SD, et al. The severe perinatal form of autosomal recessive polycystic kidney disease maps to chromosome 6p21.1-p12: implications for genetic counseling. Am J Hum Genet. 1995;56(5):1101-1107
48. Rossetti S, Torra R, Coto E, et al. A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees. Kidney Int. 2003; 64(2):391-403 doi:10.1046/j.1523-1755.2003.00111.x
49. Zvereff V, Yao S, Ramsey J, Mikhail FM, Vijzelaar R, Messiaen L. Identification of PKHD1 multiexon deletions using multiplex ligation-dependent probe amplification and quantitative polymerase chain reaction. Genet Test Mol Biomarkers. 2010;14(4): 505-510 doi:10.1089/gtmb.2009.0188
50. Consugar MB, Anderson SA, Rossetti S, et al. Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease. Am J Kidney Dis. 2005;45(1):77-87 doi:10.1053/j.ajkd.2004.09.009
51. Bergmann C, Brüchle NO, Frank V, Rehder H, Zerres K. Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation. N Engl J Med. 2008;359(3):318-319 doi:10.1056/NEJMc0801868
52. Vujic M, Heyer CM, Ars E, et al. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol. 2010;21(7):1097-1102 doi: 10.1681/ASN.2009101070
53. Bergmann C, von Bothmer J, Ortiz Brüchle N, et al. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol. 2011;22(11): 2047-2056 doi:10.1681/ASN.2010101080
54. Decramer S, Parant O, Beaufils S, et al. Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol. 2007;18(3):923-933 doi:10.1681/ASN.2006091057
55. Bergmann C. Autosomal-recessive polycystic kidney disease gets more complex. Gastroenterology. 2013;144(5):1155-1156 doi:10.1053/j.gastro.2013.02.046
56. Reuss A, Wladimiroff JW, Niermeyer MF. Sonographic, clinical and genetic aspects of prenatal diagnosis of cystic kidney disease. Ultrasound Med Biol. 1991;17(7): 687-694
57. Chaumoitre K, Brun M, Cassart M, et al. Differential diagnosis of fetal hyperechogenic cystic kidneys unrelated to renal tract anomalies: A multicenter study. Ultrasound Obstet Gynecol. 2006;28(7):911-917 doi:10.1002/uog.3856
58. Brun M, Maugey-Laulom B, Eurin D, Didier F, Avni EF. Prenatal sonographic patterns in autosomal dominant polycystic kidney disease: a multicenter study. Ultrasound Obstet Gynecol. 2004;24(1):55-61 doi: 10.1002/uog.1098
59. Luthy DA, Hirsch JH. Infantile polycystic kidney disease: observations from attempts at prenatal diagnosis. Am J Med Genet. 1985;20(3):505-517 doi: 10.1002/ajmg.1320200311
60. Zerres K, Senderek J, Rudnik-Schöneborn S, et al. New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet. 2004;66(1):53-57 doi:10.1111/j.0009-9163.2004.00259.x
61. Gaspar H, Michel-Calemard L, Morel Y, Wisser J, Stallmach T, Schinzel A. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD) without DNA from an index patient in a current pregnancy. Prenat Diagn. 2006;26(4):392-393 doi:10.1002/pd.1420
62. Gigarel N, Frydman N, Burlet P, et al. Preimplantation genetic diagnosis for autosomal recessive polycystic kidney disease. Reprod Biomed Online. 2008;16 (1):152-158
63. Thornhill AR, deDie-Smulders CE, Geraedts JP, et al; ESHRE PGD Consortium. ESHRE PGD Consortium "Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)." Hum Reprod. 2005; 20(1):35-48 doi:10.1093/humrep/deh579
64. Lau EC, Janson MM, Roesler MR, Avner ED, Strawn EY, Bick DP. Birth of a healthy infant following preimplantation PKHD1 haplotyping for autosomal recessive polycystic kidney disease using multiple displacement amplification. J Assist Reprod Genet. 2010;27(7):397-407 doi: 10.1007/s10815-010-9432-5
65. Mehler K, Beck BB, Kaul I, Rahimi G, Hoppe B, Kribs A. Respiratory and general outcome in neonates with renal oligohydramnios-a single-centre experience. Nephrol Dial Transplant. 2011;26(11): 3514-3522. doi:10.1093/ndt/gfr046doi:10.1093/ndt/gfr046
66. Klaassen I, Neuhaus TJ, Mueller-Wiefel DE, Kemper MJ. Antenatal oligohydramnios of renal origin: long-term outcome. Nephrol Dial Transplant. 2007;22(2):432-439 doi: 10.1093/ndt/gfl591
67. Beaunoyer M, Snehal M, Li L, Concepcion W, Salvatierra O Jr, Sarwal M. Optimizing outcomes for neonatal ARPKD. Pediatr Transplant. 2007;11(3):267-271 doi:10.1111/j.1399-3046.2006.00644.x
68. Bean SA, Bednarek FJ, Primack WA. Aggressive respiratory support and unilateral nephrectomy for infants with severe perinatal autosomal recessive polycystic kidney disease. J Pediatr. 1995;127(2): 311-313
69. Shukla AR, Kiddoo DA, Canning DA. Unilateral nephrectomy as palliative therapy in an infant with autosomal recessive polycystic kidney disease. J Urol. 2004; 172(5 pt 1):2000-2001 doi:10.1097/01.ju.0000142025.80132.2f
70. Arbeiter A, Büscher R, Bonzel K-E, et al. Nephrectomy in an autosomal recessive polycystic kidney disease (ARPKD) patient with rapid kidney enlargement and increased expressio n of EGFR. Nephrol Dial Transplant. 2008;23(9):3026-3029 doi: 10.1093/ndt/gfn288
71. Spechtenhauser B, Hochleitner BW, Ellemunter H, et al. Bilateral nephrectomy, peritoneal dialysis and subsequent cadaveric renal transplantation for treatment of renal failure due to polycystic kidney disease requiring continuous ventilation. Pediatr Transplant. 1999;3(3):246-248
72. Sumfest JM, Burns MW, Mitchell ME. Aggressive surgical and medical management of autosomal recessive polycystic kidney disease. Urology. 1993;42(3):309-312
73. Cole BR, Conley SB, Stapleton FB. Polycystic kidney disease in the first year of life. J Pediatr. 1987;111(5):693-699
74. Kääriäinen H, Koskimies O, Norio R. Dominant and recessive polycystic kidney disease in children: evaluation of clinical features and laboratory data. Pediatr Nephrol. 1988;2(3):296-302
75. Gagnadoux MF, Habib R, Levy M, Brunelle F, Broyer M. Cystic renal diseases in children. Adv Nephrol Necker Hosp. 1989;18: 33-57
76. Zerres K. Autosomal recessive polycystic kidney disease. Clin Investig. 1992;70(9): 794-801
77. Goto M, Hoxha N, Osman R, Dell KM. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2010; 25(12):2449-2457 doi:10.1007/s00467-010- 1621-z
78. Phillips JK, Hopwood D, Loxley RA, et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press Res. 2007;30(3): 129-144 doi:10.1159/000101828
79. Wühl E, Trivelli A, Picca S, et al; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650 doi:10.1056/NEJMoa0902066
80. Dias NF, Lanzarini V, Onuchic LF, Koch VHK. Clinical aspects of autosomal recessive polycystic kidney disease. J Bras Neurol. 2010;32(3):263-267
81. Lucaya J, Enriquez G, Nieto J, Callis L, Garcia Peña P, Dominguez C. Renal calcifications in patients with autosomal recessive polycystic kidney disease: prevalence and cause. AJR Am J Roentgenol. 1993;160(2):359-362 doi:10.2214/ajr.160.2.8424350
82. Wen J. Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Clin Transl Sci. 2011;4(6):460-465 doi:10.1111/j.1752-8062.2011.00306.x
83. Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012;54(5):580-587 doi: 10.1097/MPG.0b013e31824711b7
84. Gunay-Aygun M, Font-Montgomery E, Lukose L, et al. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology. 2013;144(1):112-121.e2 doi:10.1053/j.gastro.2012.09.056
85. Telega G, Cronin D, Avner ED. New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications. Pediatr Transplant. 2013;17(4):328-335 doi:10.1111/petr.12076
86. Higashihara E, Nutahara K, Okegawa T, et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2014;18(1)157-165 doi:10.1007/s10157-013-0834-4doi:10.1007/s10157-013-0834-4
87. Grantham JJ, Torres VE, Chapman AB, et al; CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122-2130 doi: 10.1056/NEJMoa054341
88. Fonck C, Chauveau D, Gagnadoux MF, Pirson Y, Grünfeld JP. Autosomal recessive polycystic kidney disease in adulthood. Nephrol Dial Transplant. 2001;16(8):1648-1652
89. Blickman JG, Bramson RT, Herrin JT. Autosomal recessive polycystic kidney disease: long-term sonographic findings in patients surviving the neonatal period. AJR Am J Roentgenol. 1995;164(5):1247-1250 doi:10.2214/ajr.164.5.7717240
90. Lieberman E, Salinas-Madrigal L, Gwinn JL, Brennan LP, Fine RN, Landing BH. Infantile polycystic disease of the kidneys and liver: clinical, pathological and radiological correlations and comparison with congenital hepatic fibrosis. Medicine (Baltimore). 1971;50(4):277-318
91. Avni FE, Guissard G, Hall M, Janssen F, DeMaertelaer V, Rypens F. Hereditary polycystic kidney diseases in children: changing sonographic patterns through childhood. Pediatr Radiol. 2002;32(3):169-174
92. Cassart M, Massez A, Metens T, et al. Complementary role of MRI after sonography in assessing bilateral urinary tract anomalies in the fetus. AJR Am J Roentgenol. 2004;182(3):689-695 doi:10.2214/ajr.182.3.1820689
93. Kern S, Zimmerhackl LB, Hildebrandt F, Ermisch-Omran B, Uhl M. Appearance of autosomal recessive polycystic kidney disease in magnetic resonance imaging and RARE-MR-urography. Pediatr Radiol. 2000;30(3):156-160
94. Piscaglia F, Marinelli S, Bota S, et al. The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives. Eur J Radiol. 2014;83: 450-455 doi:10.1016/j.ejrad.2013.06.009doi: 10.1016/j.ejrad.2013.06.009
95. Kummer S, Sagir A, Pandey S, et al. Liver fibrosis in recessive multicystic kidney diseases: transient elastography for early detection. Pediatr Nephrol. 2011;26(5): 725-731 doi:10.1007/s00467-011-1771-7
96. Beil S, Drube J, Gluer S, Lehner F, Ehrich JHH, Pape L. End-stage renal disease due to ARPKD in the first months of life: transplantation or dialysis?-two case reports. Pediatr Transplant. 2010;14(6):E75-E78 doi: 10.1111/j.1399-3046.2009.01167.x
97. Kashtan CE, Primack WA, Kainer G, Rosenberg AR, McDonald RA, Warady BA. Recurrent bacteremia with enteric pathogens in recessive polycystic kidney disease. Pediatr Nephrol. 1999;13(8):678-682
98. Davis ID, Ho M, Hupertz V, Avner ED. Survival of childhood polycystic kidney disease following renal transplantation: the impact of advanced hepatobiliary disease. Pediatr Transplant. 2003;7(5):364-369
99. Chapal M, Dufay A, Roussey G, et al. Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transplant. 2012;27(5):2083-2088 doi: 10.1093/ndt/gfr588doi:10.1093/ndt/gfr588
100. Khan K, Schwarzenberg SJ, Sharp HL, Matas AJ, Chavers BM. Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease. Am J Transplant. 2002;2(4):360-365
101. Charlton MR, Wall WJ, Ojo AO, et al; International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15(11):S1-S34 doi:10.1002/lt.21877
102. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant. 2008;8(11):2243-2251 doi:10.1111/j.1600-6143.2008.02416.x
103. Brinkert F, Lehnhardt A, Montoya C, et al. Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome. Transpl Int. 2013;26(6):640-650 doi:10.1111/tri.12098
104. Lilova M, Kaplan BS, Meyers KE. Recombinant human growth hormone therapy in autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2003;18(1):57-61 doi:10.1007/s00467-002-0986-z
105. Konrad M, Zerres K, Wühl E, Rudnik-Schöneborn S, Holtkamp U, Schärer K. Body growth in children with polycystic kidney disease. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Acta Paediatr. 1995;84(11):1227-1232
106. Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1824-1830 doi:10.2215/CJN.09751110
107. Lande MB, Gerson AC, Hooper SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol. 2011;6(8):1831-1837 doi:10.2215/CJN.00810111
108. Kupferman JC, Lande MB, Adams HR, Pavlakis SG. Primary hypertension and neurocognitive and executive functioning in school-age children. Pediatr Nephrol. 2013;28(3):401-408 doi:10.1007/s00467-012-2215-8
109. Lande MB, Kupferman JC, Adams HR. Neurocognitive alterations in hypertensive children and adolescents. J Clin Hypertens (Greenwich). 2012;14(6):353-359 doi: 10.1111/j.1751-7176.2012.00661.x
110. Ostrovskaya MA, Rojas M, Kupferman JC, et al. Executive function and cerebrovascular reactivity in pediatric hypertension [published online ahead of print July 22, 2013]. J Child Neurol doi: 10.1177/0883073813494264doi:10.1177/0883073813494264
111. Adams HR, Szilagyi PG, Gebhardt L, Lande MB. Learning and attention problems among children with pediatric primary hypertension. Pediatrics. 2010;126(6). Available at: www.pediatrics.org/cgi/content/full/126/6/e1425 doi:10.1542/peds.2010-1899
112. Hartung EA, Matheson M, Lande MB, et al. Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD Cohort Study [published online ahead of print May 15, 2014]. Pediatr Nephrol doi:10.1007/s00467-014-2816-5
113. Gerson AC, Wentz A, Abraham AG, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics. 2010;125(2). Available at: www.pediatrics.org/cgi/content/full/125/2/e349 doi:10.1542/peds.2009-0085
114. Neul SK, Minard CG, Currier H, Goldstein SL. Health-related quality of life functioning over a 2-year period in children with end-stage renal disease. Pediatr Nephrol. 2013;28(2):285-293 doi:10.1007/s00467-012-2313-7
115. Becker JU, Opazo Saez A, Zerres K, et al. The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease. Kidney Blood Press Res. 2010;33(2):129-138 doi:10.1159/000314380
116. Fischer D-C, Jacoby U, Pape L, et al. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant. 2009;24 (6):1819-1827 doi:10.1093/ndt/gfn744
117. Renken C, Fischer DC, Kundt G, Gretz N, Haffner D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant. 2011;26(1):92-100 doi:10.1093/ndt/gfq384
118. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820-829 doi:10.1056/NEJMoa0907419
119. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363 (9):830-840 doi:10.1056/NEJMoa1003491
120. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21(3):598-604 doi:10.1093/ndt/gfi181
121. Berthier CC, Wahl PR, Le Hir M, et al. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2008;23(3):880-889 doi:10.1093/ndt/gfm697
122. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010;21(3):489-497 doi:10.1681/ASN.2009040421
123. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA. 2006;103(14):5466-5471 doi:10.1073/pnas.0509694103
124. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005;16(1): 46-51 doi:10.1681/ASN.2004080660
125. Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57(4):1460-1471 doi:10.1046/j.1523-1755.2000.00991.x
126. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11(7):1179-1187
127. Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63(6):1983-1994 doi: 10.1046/j.1523-1755.2003.00023.x
128. Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004;66(3):964-973 doi:10.1111/j.1523-1755.2004.00843.x
129. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279(39):40419-40430 doi:10.1074/jbc.M405079200
130. Yamaguchi T, Hempson SJ, Reif GA, Hedge A-M, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol. 2006;17(1):178-187 doi: 10.1681/ASN.2005060645
131. Yasuda G, Jeffries WB. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int. 1998;54(1):80-86 doi:10.1046/j.1523-1755.1998.00990.x
132. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323-1326 doi:10.1038/nm935
133. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102-108 doi: 10.1681/ASN.2007060688
134. Torres VE, Chapman AB, Devuyst O, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25): 2407-2418 doi:10.1056/NEJMoa1205511
135. Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2013;58(1): 409-421 doi:10.1002/hep.26140
136. Caroli A, Perico N, Perna A, et al; ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebocontrolled, multicentre trial. Lancet. 2013; 382(9903):1485-1495 doi:10.1016/S0140-6736(13)61407-5
137. Sweeney WE Jr, Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res. 2006;326(3):671-685 doi: 10.1007/s00441-006-0226-0
138. Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int. 2001;60(4):1240-1248 doi:10.1046/j.1523-1755.2001.00963.x
139. Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003;64(4):1310-1319 doi:10.1046/j.1523-1755.2003.00232.x
140. Sato Y, Harada K, Kizawa K, et al. Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol. 2005;166(1): 49-60 doi:10.1016/S0002-9440(10)62231-6
141. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000;57(1):33-40 doi: 10.1046/j.1523-1755.2000.00829.x
142. Sweeney WE Jr, von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008;19 (7):1331-1341 doi:10.1681/ASN.2007060665
143. Somlo S, Guay-Woodford LM. Polycystic kidney disease. In: Lifton RP, Somlo S, Giebisch GH, Seldin DW, eds. Genetic Diseases of the Kidney. Burlington, MA: Elsevier; 2009:393-424